Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
May 01, 2024
Video
Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.
April 12, 2024
Video
Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.
April 11, 2024
Video
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
April 11, 2024
Video
Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.
April 04, 2024
Video
Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.
April 04, 2024
Video
Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
April 04, 2024
Video
Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
April 03, 2024
Video
Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.
March 29, 2024
Video
Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.
March 28, 2024
Video
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
March 28, 2024
Video
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
March 25, 2024
Video
Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.
March 21, 2024
Video
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
March 21, 2024
Video
Side effect profiles driven by fruquintinib use are discussed.
March 14, 2024
Video
Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
March 14, 2024
Video
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
March 13, 2024
Video
Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.
March 13, 2024
Video
Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.
March 07, 2024
Video
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
March 07, 2024
Video
Medical experts provide key takeaways and impacts from the FRESCO-2 study.